Genentech Biooncology
Genentech Biooncology
    • Home 

    • Tumor Types 

    • Renal Cell Carcinoma 

    • GLOSSARY
    • ON
    • OFF
  • Print
  • share
 
 
' The related resources bookmark allows you to jump directly to other pages on the site that contain information directly related to the topics you're currently exploring.
  • Home Page
  • What's New?
  • Tumor Types
    • Breast Cancer
    • CLL
    • Colorectal Cancer
    • DLBCL
    • Follicular Lymphoma
    • Gastric Cancer
    • Glioblastoma
    • Lung Cancer
    • Melanoma
    • Multiple Myeloma
    • Ovarian Cancer
    • Pancreatic Cancer
    • Renal Cell Carcinoma
    • Other Tumor Types
  • Molecular Causes of Cancer
  • Biological Pathways
  • Therapeutic Targets
  • Pipeline Molecules
  • Research Education
  • Clinical Trials
  • Resources
  • Contact Us
Register for Updates Unsubscribe Share
Register for Updates Unsubscribe Share

Related Resources for this page:

  • Biological Pathways
    • Angiogenic Signaling
      • Angiogenic Signaling
  • Therapeutic Targets
    • AKT
      • Akt
    • PI3K
      • PI3K
    • VEGF
      • VEGF
    • mTOR
      • mTOR
  • Pipeline Molecules
    • AKT Inhibitor (GDC-0068)
      • Akt Inhibitor (GDC-0068)
    • PI3K/mTOR Inhibitor (GDC-0980)
      • PI3K/mTOR Inhibitor (GDC-0980)
  • Research Education
    • ResearchVEGF
      • Biology of RCC
      • Triggers of VEGF production
      • Evidence of VEGF expression in RCC
      • Importance of interstitial pressure
      • VEGF and prognosis in RCC
      • The role of ubiquitination
      • Summary
      • Slide decks and videos
      • VEGF in renal cell carcinoma
  • Clinical Trials
    • Renal Cell Carcinoma
      • Anti-PDL1 (MPDL3280A)
      • PI3K/mTOR Inhibitor (GDC-0980)
      • Renal Cell Carcinoma
  • Future Directions
    • Antibody-Drug conjugates
      • Emerging therapeutic options
      • Emerging therapeutic options
      • VEGF expression in gastric cancer
      • HER Signaling
      • High VEGF expression
      • VEGF and prognosis in multiple myeloma
      • VEGF expression and liver metastases
      • MVD and progression
      • Hypoxic tumor environment promotes angiogenesis
      • Serum VEGF as a clinical marker
      • Regulation of VEGF expression
      • VEGF expression in multiple myeloma
      • VEGF pathways in multiple myeloma
      • Summary
      • VEGF and progression
      • VEGF in bladder cancer
      • VEGF in pancreatic cancer
      • Summary
      • Summary
      • VEGF and MVD
      • Summary
      • VEGF and prognosis
      • VEGF and prognosis in pancreatic cancer
      • VEGF and tumor progression in gastric cancer
      • VEGF and tumor progression in pancreatic cancer
      • VEGF and progression in urothelial carcinoma
      • VEGF in gastric cancer
      • VEGF in multiple myeloma
    • Apoptosis
      • Emerging therapeutic options
    • Bispecific Monoclonal Antibodies
      • Emerging therapeutic options
      • Emerging therapeutic options
      • Emerging therapeutic options
    • Glycoengineered Antibodies
      • Emerging therapeutic options
      • Emerging therapeutic options
      • VEGF expression in gastric cancer
      • HER Signaling
      • High VEGF expression
      • VEGF and prognosis in multiple myeloma
      • VEGF expression and liver metastases
      • MVD and progression
      • Hypoxic tumor environment promotes angiogenesis
      • Emerging therapeutic options
      • Serum VEGF as a clinical marker
      • Regulation of VEGF expression
      • VEGF expression in multiple myeloma
      • VEGF pathways in multiple myeloma
      • Summary
      • VEGF and progression
      • VEGF in bladder cancer
      • VEGF in pancreatic cancer
      • Summary
      • Summary
      • VEGF and MVD
      • Summary
      • VEGF and prognosis
      • VEGF and prognosis in pancreatic cancer
      • VEGF and tumor progression in gastric cancer
      • VEGF and tumor progression in pancreatic cancer
      • VEGF and progression in urothelial carcinoma
      • VEGF in gastric cancer
      • VEGF in multiple myeloma
    • Non-Antibody Biologics
      • Apoptosis
      • VEGF expression in gastric cancer
      • High VEGF expression
      • VEGF and prognosis in multiple myeloma
      • VEGF expression and liver metastases
      • MVD and progression
      • Hypoxic tumor environment promotes angiogenesis
      • Serum VEGF as a clinical marker
      • Regulation of VEGF expression
      • VEGF expression in multiple myeloma
      • What are the strategies for inhibiting the VEGF pathway?
      • VEGF pathways in multiple myeloma
      • Summary
      • VEGF and progression
      • VEGF in bladder cancer
      • VEGF in pancreatic cancer
      • Summary
      • Summary
      • VEGF and MVD
      • Summary
      • VEGF and prognosis
      • VEGF and prognosis in pancreatic cancer
      • VEGF and tumor progression in gastric cancer
      • VEGF and tumor progression in pancreatic cancer
      • VEGF and progression in urothelial carcinoma
      • VEGF in gastric cancer
      • VEGF in multiple myeloma
    • Targeted Small Molecules
      • Apoptosis
      • Emerging therapeutic options
      • Emerging therapeutic options
      • VEGF expression in gastric cancer
      • Gastric Cancer
      • High VEGF expression
      • VEGF and prognosis in multiple myeloma
      • VEGF expression and liver metastases
      • MAPK Signaling
      • Melanoma
      • MVD and progression
      • Hypoxic tumor environment promotes angiogenesis
      • Multiple Myeloma
      • Emerging therapeutic options
      • PI3K Inhibitor (GDC-0941)
      • Other Tumor Types
      • Serum VEGF as a clinical marker
      • PI3K/Akt/mTOR Signaling
      • Slide decks and videos
      • Regulation of VEGF expression
      • VEGF expression in multiple myeloma
      • What are the strategies for inhibiting the VEGF pathway?
      • VEGF pathways in multiple myeloma
      • Summary
      • VEGF and progression
      • VEGF in bladder cancer
      • VEGF in pancreatic cancer
      • Summary
      • Summary
      • VEGF and MVD
      • Summary
      • VEGF and prognosis
      • VEGF and prognosis in pancreatic cancer
      • VEGF and tumor progression in gastric cancer
      • VEGF and tumor progression in pancreatic cancer
      • VEGF and progression in urothelial carcinoma
      • VEGF in gastric cancer
      • VEGF in multiple myeloma
    • Traditional Monoclonal Antibodies
      • Anti-EGFL7
      • B-cell Surface Proteins
      • Glossary
      • Emerging therapeutic options
      • Emerging therapeutic options
      • VEGF expression in gastric cancer
      • Gastric Cancer
      • HER Signaling
      • High VEGF expression
      • VEGF and prognosis in multiple myeloma
      • VEGF expression and liver metastases
      • Melanoma
      • MVD and progression
      • Hypoxic tumor environment promotes angiogenesis
      • Emerging therapeutic options
      • Serum VEGF as a clinical marker
      • Angiogenic Signaling
      • Slide decks and videos
      • Regulation of VEGF expression
      • VEGF expression in multiple myeloma
      • What are the strategies for inhibiting the VEGF pathway?
      • VEGF pathways in multiple myeloma
      • Summary
      • VEGF and progression
      • VEGF in bladder cancer
      • VEGF in pancreatic cancer
      • Summary
      • Summary
      • VEGF and MVD
      • Summary
      • VEGF and prognosis
      • VEGF and prognosis in pancreatic cancer
      • VEGF and tumor progression in gastric cancer
      • VEGF and tumor progression in pancreatic cancer
      • VEGF and progression in urothelial carcinoma
      • VEGF in gastric cancer
      • VEGF in multiple myeloma
Share Renal Cell Carcinoma

Renal Cell Carcinoma

Disease Information

Genentech BioOncology is dedicated to advancing the science of renal cell carcinoma therapy through comprehensive research programs and education. Renal cell carcinoma forms in the renal microtubules that filter blood and remove waste products.1

Renal Cell Cancer Statistics

  • In 2010, an estimated 58,240 Americans were diagnosed with renal cancer. Of these diagnoses, 92% were renal cell carcinoma, 7% were renal pelvis carcinoma, and 7% were Wilms tumor, a childhood cancer2
    • Since 1975, incidence of kidney cancer has increased by 1.8% each year in men and 2.4% in women2
  • Renal cancer mortality in 2010 was about 13,040. Death rates for renal cancer have been decreasing2
    • Mortality in women has decreased by 0.6% per year since 19922
    • Mortality in men has decreased by 1.5% per year since 20022

Renal Cell Cancer Epidemiology

  • Risk factors include smoking; obesity; hypertension; workplace exposure to asbestos, cadmium, certain herbicides, benzene, and organic solvents; male gender (possibly related to smoking and workplace exposure to toxins); advanced renal disease; and family history of renal cell carcinoma3
    • Certain rare hereditary diseases greatly increase the risk of renal cancer (von Hippel-Lindau syndrome, Birt-Hogg-Dube syndrome, and renal oncocytoma)3
  • The 5-year relative survival rate for renal cell carcinoma is 70%2

Renal Cell Cancer Symptoms

Early renal cancer usually has no symptoms. As the tumor progresses, it may cause hematuria, a pain or lump in the lower back or abdomen, fatigue, weight loss, fever, or edema in the legs and ankles.2

Other links to renal cell carcinoma disease information

These links give a sampling of other sites offering information on renal cell carcinoma, which you may find useful in your practice.

  • National Cancer Institute at National Institutes of Health, Kidney Cancer
  • ASCO Cancer Portals - Genitourinary Cancers
  • Cancer Facts & Figures

Unless otherwise indicated, Genentech, Inc. is neither affiliated with nor endorses any of the organizations listed.

References:
1.
US Department of Health and Human Services. National Cancer Institute. www.cancer.gov/cancertopics/types/kidney. Accessed April 13, 2011.
2.
American Cancer Society. Cancer Facts & Figures 2010. www.cancer.org/acs/groups/content/@epidemiologysurveilance/
documents/document/acspc-026238.pdf
. Accessed April 14, 2011.
3.
US Department of Health and Human Services. National Cancer Institute Web site. www.cancer.gov/cancertopics/wyntk/kidney/page4. Accessed April 13, 2011.

 
  • SITEMAP
  • /
  • PRIVACY POLICY
  • /
  • TERMS & CONDITIONS
  • /
  • CONTACT US
  • /
  • © 2013 Genentech USA, Inc. All rights reserved.
  • /
  • BIO0000907901
Next section: Other Tumor Types »

© 2011 Genentech USA, Inc. All rights reserved